WHAT IS CANNABICHROMANON (CBCN)?

Cannabichromanon (CBCN) is a cannabis sativa plant compound. Its relationship with other cannabinoids is still unknown as chemists still don’t know what class or categorization this compound falls into.

Found in small quantities in the cannabis plant, this compound is yet to undergo further testing to discover its properties and relationship with other compounds.

For over 70 years, researchers have been keen on the development and study of the cannabis plant. In 1940, British scientist Robert Cahn was able to identify CBD compounds to some extent.

In 1986, a research group with the leadership of R.K. Razdan was able to analyze the structure-activity relationship (SAR) of about 300 CBD analogs based on their activity in different animals.

CBCN was one of the compounds found during one of this research, but its distinct features and difference in chemical structure from other categories and families have made it special in its own way.

Related: What is CBN?

Like all CBD compounds, CBCN is formed through the flower blooming stage of the cannabis plant. Its chemical structure and bonds are yet to be analyzed and understood. We know it forms naturally and that it is present in the plant in small quantities.

What research hasn’t been able to tell us is how its chemical components come together to become cannabichromanon (CBCN).

Relatively, the future of the CBCN is hanging on a tiny thread for a few reasons. For one, there are lots of identified compounds in the cannabis plant that research hasn’t gone into, so the bleakness of research into an uncategorized compound is visceral.

Another reason to support this thought is the small quantity in which CBCN exists. It is not present at all in some plants and when it is, it occurs in small quantities.

This, of course, is not to say, there will be no research into this compound. The future of the cannabis plant is somewhat a grey area, and we can only speculate based on observations.

HOW DOES CBCN WORK?

CBCN belongs to no known categorization of currently known cannabinoid compounds. Researchers have not been able to tell us or show us how it works – yet. Due to its lack of similarities to the THC, CBD, CBN, CBGV, and CBG compounds and their derivatives, we cannot speculate or assume how this compound works.

There is no test to tell us how it works when combined with other compounds. We do not know how it reacts to the human body receptors.

For organizational purposes, CannabiJournal has decided to group CBCN under the CBC category. Further research is warranted for this specific cannabinoid.

POSSIBLE THERAPEUTIC BENEFITS

Cannabis sativa has proven to be beneficial to human health.  CBD and its derivatives are currently being studied with respect to epilepsy, cancer, psychiatric disorders, inflammatory disorders, diabetes, neurological conditions, and brain trauma.

They have been found to have therapeutic benefits such as neuroprotective, antipsychotic, antiemetic, amongst others. The specific benefits of CBCN are yet to be known.

INTERESTING FACTS

1. CBCN doesn’t have any similarity with known cannabinoid compounds.
2. It exists in very small quantities.

References

Andre, Christelle M.; Hausman, Jean-Francois; Guerriero, Gea (2016-02-04). “Cannabis sativa: The Plant of the Thousand and One Molecules”. Frontiers in Plant Science. 7: 19. doi:10.3389/fpls.2016.00019. ISSN 1664-462X. PMC 4740396. PMID 26870049.

Grotenhermen, F (2003). “Pharmacokinetics and pharmacodynamics of cannabinoids”. Clin Pharmacokinet. 42 (4): 327–60. doi:10.2165/00003088-200342040-00003. PMID 12648025.